Mutational landscape of CBF AML. (A) Mutational, morphological, cytogenetic, and clinical information of CBF AML. Each column represents a patient sample. (B) Variant allele frequency (VAF) of mutations in activated signaling genes across t(8;21) and inv(16) genetic groups. Each bar represents a patient sample. Stars identify samples with 2 or more mutations. Note that for each mutation in a given specimen, VAFs are stacked with a no co-occurrence presumption to facilitate presentation of data. (C) Activated signaling mutations in a sample at diagnosis and relapse. (D-F) Primary structures of ASXL2, SMC1A, and ZBTB7A proteins, respectively, with corresponding positions of mutations. (G) Number of nonactivated signaling mutations in CBF AML subgroups. Statistics are based on Fisher’s exact test. ASX, additional sex combs; ASXH, ASX homology; ASXN, ASX N terminal; dx, diagnosis; FS, frameshift; MS, missense; NA, not available; NS, nonsense; PHD, plant homeodomain; rel, relapse.